Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Highly Accessed Letter

Colchicine in acute gouty arthritis: the optimum dose?

George I Varughese1* and Abraham I Varghese2

Author Affiliations

1 University Hospital of North Staffordshire, Stoke-on-Trent ST4 8HZ, UK

2 Northampton General Hospital, Northampton NN1 5BD, UK

For all author emails, please log on.

Arthritis Research & Therapy 2006, 8:405  doi:10.1186/ar2039


See related review by Cronstein and Terkeltaub, http://arthritis-research.com/content/8/S1/S3


The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/8/5/405


Published:19 September 2006

© 2006 BioMed Central Ltd.

Letter

We applaud Cronstein and Terkeltaub [1] on their comprehensive review of the inflammatory process of gout and its treatment. Although they allude to the fact that colchicine probably has the smallest therapeutic window of any drug used to treat acute gouty arthritis, they have suggested "In treating acute gouty arthritis colchicine is typically administered as an oral 0.6 mg dose, followed by 0.6 mg at hourly intervals until gastrointestinal side effects (e.g. nausea, vomiting, or diarrhea) occur or a maximum total of six to eight doses has been administered" (see also the recommended dosage in Table 1 in [1]).

This is very similar to the dosage of colchicine suggested a decade ago [2], and indeed comparable to the regimen that was also expressed in grains in Hollander's Textbook of Rheumatology in 1960 [3]. Despite the fact that there is perhaps only one double blind placebo controlled study on colchicine in acute gout where gastrointestinal side effects occurred before the relief of pain [1], and the optimal dose of colchicine still remains elusive, there has not been any significant change to the recommended dosage in acute gout nearly half a century later [1]. The suggestion to administer colchicine at frequent intervals until the development of gastrointestinal side effects is a matter of significant concern [4], from a practical perspective, in routine clinical practice.

Of late, a recent systematic review has shown that there is a lack of robust data to inform the debate on the management of a common problem such as gout and, interestingly, all of the drugs used to treat gout can have serious side effects [5]. Indeed, Morris and colleagues [6] had suggested an effective yet less toxic alternative regime with colchicine in the setting of acute gout, and such anecdotal published case reports should not be underestimated and dismissed too quickly, as they remain a valid and efficient source for signal generation and are of great value for drug safety.

Competing interests

Both the authors have been involved with and encountered patients who have been prescribed colchicine at frequent intervals as per current recommendations for acute gout, resulting in serious gastrointestinal side effects and renal impairment.

References

  1. Cronstein BN, Terkeltaub R: The inflammatory process of gout and its treatment.

    Arthritis Res Ther 2006, 8(Suppl 1):S3. PubMed Abstract | BioMed Central Full Text OpenURL

  2. Emmerson BT: The management of gout.

    N Engl J Med 1996, 334:445-451. PubMed Abstract | Publisher Full Text OpenURL

  3. Hollander JL: Arthritis and Allied Conditions: A Textbook of Rheumatology. 6th edition. Philadelphia: Lea & Febiger; 1960. OpenURL

  4. Lilley LL, Guanci R: 'Until diarrhea occurs'? There's a maximum dosage to prevent colchicine toxicity.

    Am J Nurs 1999, 99:12. OpenURL

  5. Sutaria S, Katbamna R, Underwood M: Effectiveness of interventions for the treatment of acute and prevention of recurrent gout – a systematic review.

    Rheumatology (Oxford), in press.

    2006 Apr 21

    PubMed Abstract | Publisher Full Text OpenURL

  6. Morris I, Varughese G, Mattingly P: Colchicine in acute gout.

    BMJ 2003, 327:1275-1276. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL